Industry: Biomedical Region: Italy Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A biotechnology start-up company in Italy focuses on research, development, production and sales of new chemical reagents for biomedical research and development and molecular diagnosis applications. The company's goal is to develop, produce and market products for biomedical R&D and molecular diagnosis. Compared with the products currently available in the market, these products have higher sensitivity, shorter time for drawing up the scheme and easier to use, which means increasing productivity and reducing costs for customers. Hope to provide the market with consumables (reagents) for molecular and cell biology biomedical applications, and provide customized design and production of its products according to customer requirements, which may include research and development and production; Services not available in the market at present.
Who has listed antimicrobial resistance (AMR) as one of the priority health and social challenges, and it is also one of the top ten global public health threats facing mankind. More than 700,000 people die from drug-resistant infections every year, and it will reach 10 million by 2050 (United Nations Conference on Antimicrobial Resistance, 2016). The global AMR reaction needs affordable and accessible diagnosis, which can quickly determine the susceptibility of antibacterial drugs.
The company developed a fast, reliable and easy-to-use QE-AMR assay to meet these important challenges and needs, and identified AMR by detecting bacterial mRNA or small RNA. QE-AMR is a molecular detection kit based on proprietary LIVELMIA technology. Through its GEN-LIVELMIA software, the company can easily design and develop diagnostic kits for clinically relevant drug-resistant bacteria:
Prototype series for detecting AMR gene:
Cooperation mode:
+Licensing
+Distribution partner/importer
+Joint marketing/joint operation